Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
about
Tubulin-interactive natural products as anticancer agentsAnti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma modelMitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1.Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro.Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate-conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM).Gender difference in motor impairments induced by chronic administration of vinblastine.A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies.Drugs that target dynamic microtubules: a new molecular perspectiveVinflunine: a novel antitubulin agent in solid malignancies.Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study.Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development.Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.Vinflunine: review of a new vinca alkaloid and its potential role in oncology.Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation.Vinflunine in the treatment of advanced bladder cancer.Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.Natural product and natural product derived drugs in clinical trials.Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).Vinflunine for the treatment of breast cancer.Vinflunine for the treatment of non-small cell lung cancer.Quantitative Determination of Vinpocetine in Dietary Supplements.Vinflunine in the treatment of bladder cancer.Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours.A high content, small molecule screen identifies candidate molecular pathways that regulate rod photoreceptor outer segment renewal
P2860
Q24650163-D8A96180-73E7-4D94-8B5A-D2A868C952E1Q28346776-D89F3F6D-9C58-4A8F-B7DF-BC0342682D07Q30493535-30119535-7E5D-432C-847B-C7EDAE8CBA3EQ33321973-EFDBA1C4-40C1-400D-A4E6-228133A9740EQ33572988-B1569D1E-11D3-4BCA-BB2E-6741CA8FF90CQ34065761-4CC419CA-B50C-4122-925A-15AE84E4A206Q34079047-9A52E7D9-8601-4639-8FBA-3E4EA488F14BQ35163252-B7317D3A-FF1B-49C9-98BD-BE79B48C5D96Q36268368-A143C592-FCD3-4711-8356-2AF337C3DAEFQ36372894-162478C9-E806-4230-B079-101C050C87CBQ36461596-7363C2A0-A4BD-47C8-8C41-13EE998EF090Q36611795-F05A8C64-DCAB-4914-9D84-A2B2D3270A95Q37284023-D92D3719-B11C-4698-98F6-E555E9F55AB6Q37352637-403B2899-26A5-49C2-9E4D-1F04CBE4564EQ37514607-E68D0733-B351-4F17-A9EA-F71AA837CD55Q37768280-7B0378C0-0B8A-41C0-8800-21C26D5D279FQ37797479-6769A480-E7F1-40C7-A272-E28CBA7AC95CQ37821892-8FFA32A6-7F3C-42B0-B726-27485448EC04Q37869505-10CC85F4-DCEE-44A6-9380-52FD210E33AFQ38247457-E24499B0-63DB-437B-8219-5EE414E2FC7AQ38798645-E9F1B50B-0330-4FD7-83D2-82B183E2E3DAQ38916189-E7CDFF72-B560-48D4-B4CA-C50D77986CA6Q38988627-37078E5C-2208-463E-AB7A-561DD36E0540Q41888375-91F1F37F-B4D4-40F5-B43D-FE36BED03791Q42183149-BE939FAE-84CB-4BA2-B901-9A163843D85FQ44397347-FBEC59CE-BFC1-4A05-88DE-B0CE227FCA7FQ46114395-2230CACD-BF2B-42DF-AE05-A17926D88AE5Q58726296-876630A9-D8FB-48BA-B265-161EFFF059B4
P2860
Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@ast
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@en
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@nl
type
label
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@ast
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@en
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@nl
prefLabel
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@ast
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@en
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@nl
P2093
P1476
Antimitotic and tubulin-intera ...... el fluorinated Vinca alkaloid.
@en
P2093
P304
P356
10.1016/S0006-2952(97)00505-4
P407
P577
1998-03-01T00:00:00Z